Document 1065
 DOCN  M9471065
 TI    The retroviral life cycle and safety considerations for retroviral
       mediated gene therapy (Meeting abstract).
 DT    9409
 AU    Boris-Lawrie K; Temin HM; McArdle Lab. for Cancer Res., Univ. of
       Wisconsin, Madison, WI
 SO    Gene Therapy for Neoplastic Diseases. June 26-29, 1993, Washington, DC,
       A7, 1993.. Unique Identifier : AIDSLINE ICDB/94698154
 AB    The life cycle of retroviruses makes them uniquely suited as vectors for
       gene therapy. Safety is the primary consideration when designing
       retroviral vectors and helper cells. Retroviral vectors used for gene
       therapy are based on simpler retroviruses (SRV), which do not cause
       disease in humans and ungulates. Retroviral disease in these species is
       caused by more complex retroviruses (MCRVs). We have converted the
       genome structure of an MCRV, bovine leukemia virus (BLV), to resemble
       that of a SRV. These simpler BLV vectors can replicate, and animal
       studies are underway to determine if the simple BLV is an effective
       vaccine against wild-type BLV infection. Preliminary experiments
       indicate that a simpler HIV-1 vector can also replicate. SRV versions of
       MCRVs may be useful as preventive vaccines against disease caused by
       MCRVs.
 DE    *Gene Therapy  Genetic Vectors  HIV-1/GENETICS  Human
       Retroviridae/*GENETICS/PHYSIOLOGY  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).